Collaborative Venture BostonGene NEC and JIP Join Forces in Japan

26 Aug, 2023

BostonGene, a prominent provider of cutting-edge AI-driven molecular and immune profiling solutions, has joined forces with NEC Corporation (NEC; TSE: 6701), a trailblazer in IT, network, and AI technologies, and Japan Industrial Partners (JIP), a renowned private equity firm headquartered in Tokyo.

This strategic alliance has given rise to BostonGene Japan Inc., a Tokyo-based joint venture dedicated to propelling personalized medicine and significantly elevating patient outcomes. The newly established entity will harness the robust molecular technology and sophisticated biocomputational algorithms offered by BostonGene, including their pioneering BostonGene Tumor Portrait™ tests. The objective is to expedite the development and verification of innovative precision medicine strategies.

BostonGene's cloud-based solutions, empowered by AI, coupled with their advanced bioinformatics proficiency, analytical tools, and state-of-the-art next-generation molecular and immune profiling, provide an intricate molecular-level understanding of cancer patients. This enables the identification of actionable targets, facilitating well-informed, evidence-based decisions regarding treatments. Beyond this, BostonGene extends its platform to provide a comprehensive array of services for biopharmaceutical clients, encompassing biomarker exploration, clinical trial assessments, assay design and refinement, and the creation of companion diagnostics.

Recent statistics have disclosed that one out of every four deaths in Japan can be attributed to cancer, and the mortality rate is on an upward trajectory. By integrating BostonGene's solutions into cancer care centers, a broader segment of patients will gain access to genomic testing and tailored therapies. Moreover, the adoption of BostonGene's industry solutions is set to benefit Japanese researchers and biopharma enterprises, facilitating advancements in biomarker-centric therapy development.

Andrew Feinberg, BostonGene's President and CEO, expressed enthusiasm about introducing their solutions to the Japanese market. He emphasized that the comprehensive molecular profiling and biocomputational prowess of BostonGene have the potential to significantly enhance patient outcomes and advance therapy development. Already well-established in the United States, BostonGene's solutions are poised to elevate the standard of cancer care in Japan by enabling personalized treatments and refining therapy creation.

Takayuki Morita, President and CEO of NEC Corporation, highlighted their commitment to cultivating the growth of the healthcare and life science sector. Leveraging NEC's healthcare solutions, driven by potent AI and digital technologies, is expected to catalyze transformative changes in cancer care across Japan. Furthermore, these solutions will aid Japanese pharmaceutical firms in formulating the most efficacious therapies.

Hidemi Moue, CEO of Japan Industrial Partners, expressed delight in supporting NEC's endeavor to establish a healthcare and life science enterprise by leveraging BostonGene's technology. This collaboration holds the promise of reshaping healthcare paradigms and therapeutic development in Japan.

Related News

Interview